HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USP Sounds Alarm As Delta-8 THC Noise Grows Louder In US Hemp Ingredients Market

Executive Summary

On same day USP published report on delta-8 THC, former FDA executive who led a marijuana policy working group while there advised that banishing the ingredient won’t come any easier than controlling the use of hemp ingredients in non-drug products subject to the agency’s regulatory oversight.

You may also be interested in...



Emerging US Cannabinoid Market Sales Driver Could Drive Lawful Use Legislation Off The Rails

Delta-8 THC is a close chemical cousin to the substance recognized for intoxicating effects. Its effects aren't a settled question, along with whether it meets definition of hemp stated in 2018 farm bill.

Perrigo Steers Through Transportation Obstacles, Soaring Shipping Costs From COVID-19

Perrigo largely has resolved distribution problems, but shipping freight costs still are much higher than pre-pandemic and it must divest a wound-care brand before US regulators sign off on acquisition of HRA Pharma, says CEO Murray Kessler during J.P. Morgan conference.

In Flip Of Bausch Health’s Planned Order For IPOs, Bausch + Lomb Registration Comes Before Solta

“We are positioned to move forward with either the Bausch + Lomb or Solta IPO quickly when market conditions are right for each of them,” CEO Joseph Papa says at J.P. Morgan conference, but the firm’s “next step” in the process of separating the two businesses was filing with the SEC an IPO registration for Bausch + Lomb.

Topics

UsernamePublicRestriction

Register

RS152007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel